ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 25, 2013
Surveying 3Q Performance from Big Pharma: Bristol-Myers, Eli Lilly, and AbbVie
Let’s take a look at the third-quarter performance of a few pharmaceutical firms.
Sep 23, 2013
Niaspan Generic Could Boost Teva
Teva’s generic version of Niaspan will hit the market shortly.
Aug 5, 2013
Which Sectors Are Leading the Market Higher? And Why Is This Important?
Identifying sector and industry leadership is very important for the institutional money manager as doing so often leads to undervalued firms that are just starting to have their value recognized by the market — Valuentum stocks. Let’s dig into which sectors have been strong and which ones have been weak so far in 2013.
Jul 31, 2013
Amgen’s Second Quarter Doesn’t Disappoint
Amgen posted a solid second quarter, but we think shares look fairly valued.
Jul 29, 2013
AbbVie’s Humira Continues to Drive Strong Performance; Pipeline Advances
Humira continues to drive strong performance in the second quarter, while AbbVie's pipeline advances.
Jul 18, 2013
Abbott's Nutrition Business Leads the Charge in Its Second Quarter
Abbott continues to be an international growth story. Let's dig into the firm's second-quarter numbers.
Jan 30, 2013
Pfizer and Eli Lilly Report Strong Performance; Drug Pipelines Continue to Advance
Let's take a look at Pfizer's and Lilly's fourth-quarter reports.
Jan 2, 2013
Valuentum's January Edition of Its Dividend Growth Newsletter!
The January edition of our Dividend Growth Newsletter is now available.
Dec 18, 2012
Inside the New Abbott: A Lot Like the Old Abbott But Without Humira
We take a dive inside the prospects of the “new” Abbott, which is quite a bit like the old Abbott—minus Humira.
Dec 11, 2012
Inside AbbVie: A Look at a New Pharmaceutical Giant
Let's take a look at Abbott's new standalone business, AbbVie.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.